$AXG

AX Coin, a subsidiary of Solowin Holdings (AXG), partners with ARP Digital on institutional liquidity and settlement

AX Coin, a subsidiary of Solowin Holdings (AXG), has partnered with ARP Digital to connect regulated stablecoin infrastructure with institutional liquidity and settlement services. AX Coin, the first licensed stablecoin issuer regulated by the Central Bank of Bahrain, will leverage ARP Digital's OTC desk and settlement rails to enable faster, more efficient cross-border value movement. The partnership initially focuses on Bahrain and the UAE, with plans to expand globally.

Original reporting
Published Sep 29, 2026, 1:10 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 29, 2026, 2:14 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AX Coin, a subsidiary of Solowin Holdings (AXG), partners with ARP Digital on institutional liquidity and settlement — source image
Decision brief

The 30-second read

$AXGNeutralLow
01

Why it matters

The collaboration with ARP Digital aims to bridge regulated stablecoin issuance with institutional liquidity, potentially expanding AX Coin's user base and transaction volume.

02

Market read

The announcement introduces a new institutional channel for a regulated, Sharia‑compliant stablecoin, which could attract fintech and Islamic finance participants in the GCC.

03

What to watch

Regulatory changes in other jurisdictions and competition from other stablecoin providers could affect long‑term adoption.

Relevance 5/10Novelty 5/10Timing: today

Background

Solowin Holdings (AXG) operates a dual‑token platform and recently secured a stablecoin issuer license in Bahrain, positioning itself as the first Sharia‑compliant stablecoin provider.

Company-level read

Ticker impact

$AXGNeutralMedium confidence
Context

AX Coin, a subsidiary of Solowin Holdings (Nasdaq: AXG), announced a strategic partnership with ARP Digital to provide institutional OTC liquidity and settlement infrastructure for its Sharia‑compliant stablecoin.

Expected impact

likely modest upside pressure as investors price in expanded institutional usage of the stablecoin.

Evidence & confidence

The deal is a first‑time announcement with clear commercial benefits, but the scale is limited to the GCC region and no financial terms were disclosed.

Market effects

May boost the broader GCC fintech and stablecoin sector by demonstrating regulatory‑compliant institutional use cases.

Could enhance Bahrain and UAE's positioning as hubs for regulated digital assets.

Limited to niche Islamic finance market; modest relevance to global crypto and fintech investors.

Counterpoint

The partnership may not translate into significant revenue without clear pricing or volume commitments, limiting stock impact.

Key entities

  • Solowin Holdings

    Parent of AX Coin, listed on Nasdaq under ticker AXG.

  • ARP Digital

    Regulated digital capital infrastructure platform operating in Bahrain and the UAE.

Related articles

$AAPLMed

Here's Everything New and Different About Apple's MacBook Pro M6

Apple launched the 14-inch MacBook Pro with the M6 chip, featuring a 12-core CPU, 12-core GPU, and 32-core Neural Engine. The M6 offers up to 30% faster graphics and 25% faster AI workloads. It supports Wi-Fi 7, Bluetooth 6, and two 4K displays at 165Hz. Pricing starts at $1,999, with preorders open and availability from November 6.

$MRKHighAI 9/10

Personalized mRNA Vaccine Reduces Melanoma Recurrence Risk in Phase 3 Trial

A phase 3 trial showed that intismeran autogene plus pembrolizumab (Keytruda) reduced melanoma recurrence risk by 42% vs. pembrolizumab alone. 24-month recurrence-free survival was 82.2% for the combo vs. 70.0% for pembrolizumab. The trial, presented at ESMO 2026, involved 1,137 patients with resected stage IIB–IV melanoma. Intismeran is an individualized mRNA-based therapy. Merck Sharp & Dohme sponsored the study.

$GMABHighAI 9/10

Genmab reports 50% lower death risk in Phase 3 trial

Genmab reported that its petosemtamab combination reduced the risk of death by 50% in a Phase 3 head-and-neck cancer trial, meeting both primary endpoints. The study involved 699 patients. Genmab's shares rose 15.22% to $51.47 on Wednesday. The company plans to discuss results with global regulators.